Lilly to supply us with 388,000 doses of esevimab for treatment of COVID-19
(RTTNews) – Eli Lilly and Co. (LLY) has said it will provide 388,000 doses of etesevimab to the U.S. government for treatment of COVID-19. Additional doses of etesevimab will be combined with existing bamlanivimab purchased by the US government.
As part of the deal, Lilly will provide 388,000 doses of etesevimab to complement doses of bamlanivimab previously purchased by the U.S. government, with approximately 200,000 doses expected to ship in Q3 2021 and the rest to be shipped in Q4. trimester.
Lilly expects the transaction to generate around $ 330 million in revenue in the second half of 2021.
Bamlanivimab and etesevimab together are authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients (aged 12 years and over weighing at least 40 kg) with positive direct SARS-CoV-2 viral test results, and who are at high risk of progression to severe COVID-19, including hospitalization or death.
The use of bamlanivimab and etesevimab is not permitted in US states, territories, and jurisdictions in which the combined frequency of variants resistant to bamlanivimab and etesevimab exceeds 5%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.